Literature DB >> 9662051

Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?

A Chico1, A Pérez, A Córdoba, R Arcelús, G Carreras, A de Leiva, F González-Sastre, F Blanco-Vaca.   

Abstract

The high risk of cardiovascular disease in patients with diabetes mellitus, particularly in those with nephropathy, is not completely explained by classical risk factors. A high plasma homocysteine concentration is an independent risk factor for cardiovascular disease but information on its association with diabetes is limited. Fasting homocysteine concentrations were measured in the plasma of 165 diabetic patients (75 with insulin-dependent [IDDM]; 90 with non-insulin-dependent diabetes [NIDDM]) and 56 non-diabetic control subjects. Other measurements included the prevalence of diabetic complications, glycaemic control, lipid and lipoprotein levels, vitamin status and renal function tests. Patients with NIDDM had higher homocysteine levels than control subjects, whereas IDDM patients did not (9.2 +/- 4.5 vs 7.7 +/- 2 micromol/l, p < 0.01; and 7.0 +/- 3 vs 7.4 +/- 2 micromol/l, NS). Univariate correlations and multiple regression analysis showed albumin excretion rate to be the parameter with the strongest independent association with homocysteine. Patients with both types of diabetes and nephropathy had higher plasma homocysteine concentrations than those without nephropathy. Increases of homocysteine in plasma were related to increases in the severity of the nephropathy. Fasting hyperhomocysteinaemia was considered as the mean of the plasma homocysteine for all control subjects (7.5 +/- 2.1 micromol/l) + 2 SD (cut-off = 11.7 micromol/l). Nephropathy was present in 80 % of diabetic patients with fasting hyperhomocysteinaemia. In conclusion, increases in fasting homocysteine in diabetic patients are associated with increased albumin excretion rate, especially in those with NIDDM, thus providing a potential new link between microalbuminuria, diabetic nephropathy and cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662051     DOI: 10.1007/s001250050969

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  24 in total

1.  Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in Type 2 diabetes mellitus.

Authors:  J Sun; Y Xu; Y Zhu; H Lu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

2.  Association between plasma homocysteine and microalbuminuria in persons without hypertension, diabetes mellitus, and cardiovascular disease.

Authors:  Charumathi Sabanayagam; Anoop Shankar
Journal:  Clin Exp Nephrol       Date:  2010-11-03       Impact factor: 2.801

3.  Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: a meta-analysis.

Authors:  Elias Zintzaras; Katrin Uhlig; George N Koukoulis; Afroditi A Papathanasiou; Ioannis Stefanidis
Journal:  J Hum Genet       Date:  2007-09-06       Impact factor: 3.172

4.  Plasma homocysteine levels in noninsulin-dependent diabetes mellitus with retinopathy and neovascular glaucoma.

Authors:  Iclal Yücel; Gültekin Yücel; Filiz Müftüoglu
Journal:  Int Ophthalmol       Date:  2005-09-29       Impact factor: 2.031

5.  Mild hyperhomocysteinemia and the common C677T polymorphism of methylene tetrahydrofolate reductase gene are not associated with the metabolic syndrome in Type 2 diabetes.

Authors:  G T Russo; A Di Benedetto; E Alessi; R Ientile; A Antico; G Nicocia; R La Scala; E Di Cesare; G Raimondo; D Cucinotta
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

6.  Impaired coronary blood flow may be related to elevated homocysteine levels in patients with metabolic syndrome.

Authors:  Yusuf I Alihanoglu; Bekir S Yildiz; Emin E Özcan; Ismail D Kilic; Deniz S Kuru; Ozgur Taskoylu; Halil Tanriverdi; Havane A Kaftan; Harun Evrengul
Journal:  Wien Klin Wochenschr       Date:  2015-09-16       Impact factor: 1.704

7.  Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics.

Authors:  Mabrouka El Oudi; Zied Aouni; Haroun Ouertani; Chakib Mazigh; Salem Machghoul
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

8.  Homocysteine as a risk factor for development of microalbuminuria in type 2 diabetes.

Authors:  Eun-Hee Cho; Eun Hee Kim; Won Gu Kim; Eun Hui Jeong; Eun Hee Koh; Woo-Je Lee; Min-Seon Kim; Joong-Yeol Park; Ki-Up Lee
Journal:  Korean Diabetes J       Date:  2010-06-30

9.  Homocysteine, an additional factor, is linked to osteoporosis in postmenopausal women with type 2 diabetes.

Authors:  Li Jianbo; Hongman Zhang; Lingfei Yan; Min Xie; Yan Mei; Chen Jiawei
Journal:  J Bone Miner Metab       Date:  2013-12-24       Impact factor: 2.626

10.  Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes.

Authors:  H C Looker; A Fagot-Campagna; E W Gunter; C M Pfeiffer; K M Venkat Narayan; W C Knowler; R L Hanson
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.